Therapeutic Advances in Multiple Sclerosis
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (31 March 2026) | Viewed by 1763
Editors
Interests: anatomy; histology; new cancer drugs; neurodegenerative diseases; multiple sclerosis
Special Issues, Collections and Topics in MDPI journals
Interests: cancer and anticancer peptides; substance P/neurokinin-1 receptor system; neurokinin-1 receptor antagonists
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Multiple sclerosis (MS) is a disease of etiology unknown and is characterized by inflammatory and demyelination processes. This inflammatory and autoimmune pathology provokes neurodegeneration in young adults, and has a higher prevalence in women than in men. The first symptoms can be ignored because they can be resolved without conspicuous disability; this aspect of the pathology typically leads to the underestimation of the disease’s prevalence. The handicap of this neurodegenerative disease is paired to its evolution, and most patients start with the “Relapsing Remitting” form, which makes this pathology an intermittently silent disease. Thus, the handicap increases when the disease evolves and depending on the stage of the pathology. Therefore, the handicap will be more or less reduced at the beginning and, unfortunately, disability will increase over time. Furthermore, the pathology evolves from the “Relapsing Remitting” form with onset being spaced out over time to the “Secondary Progressive” forms, in which the patient worsens throughout the process. Multiple Sclerosis has no cure to date, but there are several drugs available for treatment. Most of them are still focused on “Relapsing Remitting” forms, and scarce drugs are available for “Secondary Progressive” forms. In addition, more effort must be dedicated to the early detection of the pathology, the transition from RRMS to SPMS, and the better follow-up of patients. Consequently, it should be a priority nowadays to focus more efforts into the early detection of the pathology and drugs that can delay or inhibit the evolution from RRMS to SPMS, decreasing disability and increasing quality of life.
Therefore, in this Special Issue, we welcome original research, brief research reports, systematic reviews, and reviews; we would like to present the latest advances in MS therapies and diagnostic tools, including but not limited to the development of new drug candidates (preclinical and clinical) for Multiple Sclerosis treatment. All studies that represent significant advances in relation to Multiple Sclerosis, as well as those presenting prediction or evolution markers, are welcomed.
It should be remarked that IJMS is a journal of molecular science; for this reason, pure clinical studies will not suitable for this Special Issue. Anyhow, clinical or pure model submissions with biomolecular experiments are also welcomed.
Dr. Arturo Mangas
Prof. Dr. Rafael Coveñas Rodríguez
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple sclerosis
- neurodegenerative disease
- chronic disease
- autoimmune disease
- biological markers
- new drugs
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
